GXO Logistics Inc vs Heron Therapeutics Inc — how do they compare? GXO Logistics Inc trades at $46.56 (market cap $5.32B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: GXO Logistics Inc is far larger — about 78.2× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (1,891,941 versus 1,255,816). Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Heron Therapeutics Inc for 35 Days on average.
| GXO | HRTX | |
|---|---|---|
Market Cap | $5.32B | $68.01M |
Volume | 1,255,816 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $65.59 | $1.49 |
52-Week Low | $44.17 | $0.27 |
Typical Hold Time | 28 Days | 35 Days |
Enterprise Value | $10.67B | $174.75M |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.36, up 0.8% with neutral technical indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and strong analyst support (88.9% buy ratings). Recent strategic partnerships with Columbia Sportswear and aerospace/defense expansion signal growth potential, though margins remain thin with net income at 0.96%.
GXO presents a compelling growth story with 42% upside to consensus price target of $66.67. Key catalysts include logistics industry recovery and operational efficiency initiatives, but investors face margin pressure risks and competitive threats in the contract logistics space that could limit profitability expansion.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →